George Morgan

ORCID: 0000-0003-2014-3415
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Hemophilia Treatment and Research
  • Platelet Disorders and Treatments
  • Liver Disease Diagnosis and Treatment
  • Health Systems, Economic Evaluations, Quality of Life
  • Foreign Body Medical Cases
  • Child and Adolescent Health
  • Antiplatelet Therapy and Cardiovascular Diseases
  • Liver Disease and Transplantation
  • Health and Wellbeing Research
  • Ureteral procedures and complications
  • Diverse Scientific Research in Ukraine
  • Restraint-Related Deaths
  • Autopsy Techniques and Outcomes
  • Behavioral Health and Interventions
  • Physical Activity and Health
  • Venous Thromboembolism Diagnosis and Management
  • Pancreatitis Pathology and Treatment
  • Autoimmune Bullous Skin Diseases
  • Organ and Tissue Transplantation Research
  • Global Health Care Issues
  • Diabetes Treatment and Management
  • Paranormal Experiences and Beliefs
  • Coagulation, Bradykinin, Polyphosphates, and Angioedema
  • Pelvic floor disorders treatments
  • Consumer Market Behavior and Pricing

Health Education North West
2024

Element Six (United Kingdom)
2020-2023

Sci-Tech Daresbury
2023

Sherwood Forest Hospitals NHS Foundation Trust
2014

Colorado State University
2012

Non-alcoholic steatohepatitis (NASH) leads to cirrhosis and is associated with a substantial socioeconomic burden, which, coupled rising prevalence, growing public health challenge. However, there are few real-world data available describing the impact of NASH.The Global Assessment Impact NASH (GAIN) study prevalence-based burden illness across Europe (France, Germany, Italy, Spain, UK) USA. Physicians provided demographic, clinical, economic patient information via an online survey. In...

10.1016/j.jhepr.2020.100142 article EN cc-by-nc-nd JHEP Reports 2020-07-15

Abstract Introduction People with inherited and long‐term conditions such as haemophilia have been shown to adapt their levels of disability, often reporting better quality life (QoL) than expected from the general population (the disability paradox). Aim To investigate paradox in people United States by examining preference differences health state valuations versus population. Methods We conducted a discrete choice experiment including duration capture states based on patient‐reported...

10.1111/hae.14278 article EN cc-by-nc Haemophilia 2021-02-17

To study the effects of college students' physical activity and gender on depressive suicidal symptoms.The National College Health Assessment survey was administered to students nationwide. Data were analyzed with 4x2 ANOVAs Games-Howell post hoc tests when appropriate.More frequent related less symptoms consideration suicide, but not attempted suicide. Males reported frequently than did females.Depression research has implications for an increasingly sedentary population. Institutions...

10.5993/ajhb.36.2.8 article EN American Journal of Health Behavior 2012-01-25

Gene therapy has shown promise in clinical trials for patients with haemophilia, but patient preference studies have focused on factor replacement treatments.We conducted a discrete choice experiment (DCE) to investigate the relative importance and differential preferences provide gene attributes.We surveyed male adults haemophilia United States recruited from panels including National Hemophilia Foundation Community Voices Research platform using an online survey over 4 months 2020/21....

10.1111/hae.14383 article EN cc-by-nc-nd Haemophilia 2021-07-26

With the development of gene therapy for people with haemophilia (PWH), it is important to understand how impacted by (PIH) and clinicians prioritise treatment attributes support informed decisions.To examine attribute preferences PIH clinical experts in United Kingdom (UK) develop a profile characteristics fit use future discrete choice experiments (DCEs).Semi-structured interviews were conducted (n = 14) 6) who ranked pre-defined importance. Framework analysis was identify key themes...

10.1111/hae.14572 article EN cc-by-nc-nd Haemophilia 2022-04-19

Von Willebrand disease (VWD) is one of the most common inherited bleeding disorders, imposing a substantial health impact and financial burden. The Cost von in Europe: A Socioeconomic Study (CVESS) characterises socio-economic cost VWD across Germany, Spain, Italy, France, UK.A retrospective, cross-sectional design captured 12 months patient management, collected from August-December 2018, for 974 patients. This enabled estimation direct medical, non-medical indirect costs, utilising...

10.1177/10760296221120583 article EN cc-by-nc Clinical and Applied Thrombosis/Hemostasis 2022-01-01

10.1139/t67-031 article EN Canadian Geotechnical Journal 1967-05-01

Recent international guidelines conditionally recommend von Willebrand factor (VWF) prophylaxis for disease (VWD) patients with a history of severe/frequent bleeds. This post hoc analysis the Cost VWD Across Europe, Socioeconomic Study (CVESS; conducted in 2018), assessed patient characteristics and burden aged >1 year congenital not receiving but potentially eligible based on bleeds, those previous 12 months. Data were collected using medical records questionnaire. Patients considered...

10.1177/10760296221130334 article EN Clinical and Applied Thrombosis/Hemostasis 2022-01-01

10.1177/003591571000301588 article EN Proceedings of the Royal Society of Medicine 1910-06-01

10.1016/s0140-6736(01)76010-2 article EN ˜The œLancet 1896-10-01

10.1016/s0140-6736(01)54649-8 article EN ˜The œLancet 1907-04-01

10.1177/003591572702001217 article EN Proceedings of the Royal Society of Medicine 1927-10-01

Haemophilia A is a bleeding disorder caused by deficiency of coagulation factor VIII (FVIII) which leads to severe and repeated bleedings. There need understand the optimal treatment pathway for FVIII inhibitors with use immune tolerance induction (ITI) role haemostatic 'bypassing' agents (BPA) on-demand (OD) or prophylactically (Px). The aim this study was gain better understanding real-world BPA therapy administered concomitant ITI, an inhibitor replacement in patients haemophilia...

10.1186/s13023-023-02654-0 article EN cc-by Orphanet Journal of Rare Diseases 2023-03-07
Coming Soon ...